For example, the GLP-1R (glucagon-like peptide-1 receptor) agonist, an exenatide commonly used to treat type 2 diabetes, has been suggested as a potential therapeutic compound for FRDA [79,80,81]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.